Warning: The NCBI web site requires JavaScript to function. more...
Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer.
Rexhepaj E, Brennan DJ, Holloway P, Kay EW, McCann AH, Landberg G, Duffy MJ, Jirstrom K, Gallagher WM.
Breast Cancer Res. 2008;10(5):R89. Epub 2008 Oct 23.
Related citations
Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
Słodkowska J, Filas V, Buszkiewicz E, Trzeciak P, Wojciechowski M, Koktysz R, Staniszewski W, Breborowicz J, Rojo MG.
Folia Histochem Cytobiol. 2010 Jan 1;48(1):19-25.
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.
Breast Cancer Res. 2008;10(5):R88. Epub 2008 Oct 17.
pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.
Soubeyran I, Quénel N, Coindre JM, Bonichon F, Durand M, Wafflart J, Mauriac L.
Br J Cancer. 1996 Oct;74(7):1120-5.
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.
Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM.
Breast Cancer Res Treat. 2009 Jan;113(2):275-83. Epub 2008 Mar 4.
A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.
Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.
Breast Cancer Res. 2008;10(5):R74. Epub 2008 Sep 4.
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK.
Int J Cancer. 2000 Mar 20;89(2):111-7.
Quantitative immunohistochemistry using the CAS 200/486 image analysis system in invasive breast carcinoma: a reproducibility study.
Makkink-Nombrado SV, Baak JP, Schuurmans L, Theeuwes JW, van der Aa T.
Anal Cell Pathol. 1995 Apr;8(3):227-45.
Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer.
Han W, Han MR, Kang JJ, Bae JY, Lee JH, Bae YJ, Lee JE, Shin HJ, Hwang KT, Hwang SE, Kim SW, Noh DY.
BMC Cancer. 2006 Apr 12;6:92.
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H, Slamon DJ.
J Natl Cancer Inst. 2003 Jan 15;95(2):142-53.
An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.
Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.
Acta Oncol. 2009;48(4):522-31.
Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status.
Clarke RB, Laidlaw IJ, Jones LJ, Howell A, Anderson E.
Br J Cancer. 1993 Mar;67(3):606-11.
Semi-automated imaging system to quantitate estrogen and progesterone receptor immunoreactivity in human breast cancer.
Sharangpani GM, Joshi AS, Porter K, Deshpande AS, Keyhani S, Naik GA, Gholap AS, Barsky SH.
J Microsc. 2007 Jun;226(Pt 3):244-55.
Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP, Hoop JG, van Beers M, van Rodijnen N, Pannebakker M, Nap M.
Cytometry B Clin Cytom. 2005 Mar;64(1):43-52.
Immunocytochemical determination of estrogen and progesterone receptors on 219 fine-needle aspirates of breast cancer. A prospective study.
Marrazzo A, Taormina P, Leonardi P, Lupo F, Filosto S.
Anticancer Res. 1995 Mar-Apr;15(2):521-6.
Automated image analysis for high-throughput quantitative detection of ER and PR expression levels in large-scale clinical studies: the TEAM Trial Experience.
Faratian D, Kay C, Robson T, Campbell FM, Grant M, Rea D, Bartlett JM.
Histopathology. 2009 Nov;55(5):587-93.
Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
Saji S, Omoto Y, Shimizu C, Warner M, Hayashi Y, Horiguchi S, Watanabe T, Hayashi S, Gustafsson JA, Toi M.
Cancer Res. 2002 Sep 1;62(17):4849-53.
In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.
Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.
BMC Cancer. 2009 Jun 16;9:185.
Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL, Sugimoto Y, Liu S, Ye W, Wang LS, Huang YW, Lin YC.
Anticancer Res. 2006 May-Jun;26(3A):1773-84.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on